Canadian Cancer Trials Group Bulletins

General


Recent Publications

Certification for Biobanks: A Program Developed by the Canadian Tumour Repository Network (CTRNet)

The CTRNet certification program comprises registration and certification steps as two linked phases. In the registration phase, launched in November 2011, biobanks are registered into the system and individuals complete an introductory educational module. In the subsequent certification phase, the type of biobank is classified and assigned relevant educational modules and adoption of relevant standards of practice is confirmed through review of documentation including policies and protocols that address the CTRNet Required Operational Practices (ROPs). An important feature of the program is that it is intended for all types of tumour biobanks, so the scope and extent of assessment is scaled to the type of biobank. This program will provide an easily adoptable and flexible mechanism to communicate common standards through education and address both quality assurance and governance across the broad spectrum of biobanks.

Canadian Cancer Trials Group, through the leadership of Lois Shepherd, actively participates in CTRNet activities.

Matzke EAM, O'Donoghue S, Barnes RO, Daudt H, Cheah S, Suggitt A, Bartlett J, Damaraju S, Johnston R, Murphy L, Shepherd L, Mes-Masson AM, Schacter B, Watson PH. Certification for Biobanks: The Program Developed by the Canadian Tumour Repository Network (CTRNet). Biopreservation and Biobanking 10: 426-32, 2012.

http://online.liebertpub.com/doi/abs/10.1089/bio.2012.0026

____________________________________


Canadian Cancer Trials Group BR.21 -- Phase III Trial of Erlotinib Versus Placebo in Previously Treated Advanced Non-Small-Cell Lung Cancer

The authors investigated the predictive and prognostic effects of VeriStrat, a serum or plasma-based assay, on response and survival in a subset of patients enrolled on the Canadian Cancer Trials Group BR.21 trial and found that VeriStrat is predictive of objective response to erlotinib. VeriStrat is prognostic for both OS and progression-free survival, independent of clinical features, but is not predictive of differential survival benefit of erlotinib versus placebo.

Carbone DP, Ding K, Roder H, Grigorieva J, Roder J, Tsao MS, Seymour L, Shepherd FA. Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the Canadian Cancer Trials Group BR.21 Trial. J Thoracic Oncol 7: 1653-60, 2012.

http://journals.lww.com/jto/Abstract/2012/11000/Prognostic_and_Predictive_Role_of_the_VeriStrat.6.aspx